Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Todd E Simpson. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Todd E Simpson har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:XNCR / Xencor, Inc. | Director | 13 686 |
US:SGEN / Seagen Inc | Chief Financial Officer | 0 |
US:NLTX / Neoleukin Therapeutics, Inc. | Director | 25 000 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Todd E Simpson. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp XNCR / Xencor, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i XNCR / Xencor, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel XNCR / Xencor, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i XNCR / Xencor, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Todd E Simpson som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-16 |
|
4 | XNCR |
Xencor Inc
Common Stock |
A - Award | 13 686 | 13 686 | |||||
2023-12-15 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | −93 292 | 0 | −100,00 | 229,00 | −21 363 868 | ||
2023-09-22 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −80 | 128 723 | −0,06 | 206,50 | −16 520 | 26 581 300 |
2023-09-01 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 122 | 128 803 | −1,62 | 206,97 | −439 182 | 26 657 829 |
2023-08-30 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −485 | 130 925 | −0,37 | 206,00 | −99 910 | 26 970 550 |
2023-08-30 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1 225 | 131 410 | 0,94 | ||||
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | X | −1 540 | 130 185 | −1,17 | 193,87 | −298 558 | 25 238 823 |
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | X | −861 | 131 725 | −0,65 | 193,87 | −166 921 | 25 537 381 |
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | X | −1 106 | 132 586 | −0,83 | 193,87 | −214 419 | 25 704 302 |
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 14 746 | 133 692 | 12,40 | ||||
2023-04-12 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −40 364 | 118 946 | −25,34 | 204,74 | −8 264 125 | 24 353 004 |
2023-04-12 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 40 364 | 159 310 | 33,93 | 46,37 | 1 871 679 | 7 387 205 | |
2023-04-12 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −14 980 | 118 946 | −11,19 | 204,14 | −3 058 017 | 24 281 636 |
2023-04-12 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 14 980 | 133 926 | 12,59 | 46,37 | 694 623 | 6 210 149 | |
2023-04-07 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −243 | 118 946 | −0,20 | 205,86 | −50 023 | 24 485 819 |
2023-04-07 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 609 | 119 189 | 0,51 | ||||
2023-04-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1 395 | 118 580 | 1,19 | ||||
2023-03-10 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −6 082 | 117 185 | −4,93 | 177,37 | −1 078 764 | 20 785 103 |
2023-03-10 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −26 449 | 123 267 | −17,67 | 176,71 | −4 673 803 | 21 782 512 |
2023-03-10 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −10 262 | 149 716 | −6,41 | 175,89 | −1 804 983 | 26 333 547 |
2023-03-10 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 42 793 | 159 978 | 36,52 | 45,30 | 1 938 523 | 7 247 003 | |
2023-02-28 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −20 000 | 117 185 | −14,58 | 182,53 | −3 650 600 | 21 389 778 |
2023-02-21 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −39 946 | 137 185 | −22,55 | 160,00 | −6 391 400 | 21 949 737 |
2023-02-21 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 39 946 | 177 131 | 29,12 | 39,15 | 1 563 886 | 6 934 679 | |
2022-09-01 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 064 | 137 185 | −1,48 | 154,41 | −318 712 | 21 183 353 |
2022-09-01 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 122 | 139 249 | −1,50 | 154,41 | −327 668 | 21 502 065 |
2022-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 106 | 141 371 | −0,78 | 170,22 | −188 258 | 24 063 479 |
2022-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −861 | 142 477 | −0,60 | 170,22 | −146 555 | 24 251 737 |
2022-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 15 447 | 143 338 | 12,08 | ||||
2022-05-16 |
|
4 | NLTX |
Neoleukin Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2022-04-22 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −567 | 127 891 | −0,44 | 144,32 | −81 829 | 18 457 050 |
2021-12-22 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −345 | 128 458 | −0,27 | 149,85 | −51 698 | 19 249 431 |
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Incentive Stock Option (right to buy) |
M - Exercise | −2 156 | 0 | −100,00 | ||||
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 2 156 | 128 803 | 1,70 | 46,37 | 99 974 | 5 972 595 | |
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −40 232 | 0 | −100,00 | ||||
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −40 232 | 126 647 | −24,11 | 185,00 | −7 442 920 | 23 429 695 |
2021-11-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 40 232 | 166 879 | 31,77 | 44,09 | 1 773 829 | 7 357 695 | |
2021-11-02 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −33 564 | 0 | −100,00 | ||||
2021-11-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −33 564 | 126 647 | −20,95 | 180,00 | −6 041 523 | 22 796 473 |
2021-11-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 33 564 | 160 211 | 26,50 | 41,04 | 1 377 467 | 6 575 059 | |
2021-09-27 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 201 | 126 647 | 0,16 | 166,22 | 33 410 | 21 051 264 | |
2021-09-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 122 | 126 446 | −1,65 | 167,52 | −355 468 | 21 181 665 |
2021-09-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 865 | 128 568 | −1,43 | 167,52 | −312 416 | 21 537 133 |
2021-08-18 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
A - Award | 26 427 | 26 427 | |||||
2021-08-18 |
|
4 | SGEN |
Seagen Inc.
Incentive Stock Option (right to buy) |
A - Award | 642 | 642 | |||||
2021-08-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 11 095 | 130 433 | 9,30 | ||||
2021-08-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −533 | 119 338 | −0,44 | 154,55 | −82 377 | 18 444 165 |
2021-05-13 |
|
4 | NLTX |
Neoleukin Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −33 669 | 0 | −100,00 | ||||
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Incentive Stock Option (right to buy) |
M - Exercise | −1 104 | 0 | −100,00 | ||||
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 1 104 | 119 871 | 0,93 | 45,30 | 50 011 | 5 430 156 | |
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −33 669 | 118 767 | −22,09 | 200,00 | −6 733 800 | 23 753 400 |
2020-12-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 33 669 | 152 436 | 28,35 | 26,10 | 878 761 | 3 978 580 | |
2020-11-09 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | −7 509 | 118 767 | −5,95 | 180,37 | −1 354 383 | 21 421 766 | |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −469 | 126 276 | −0,37 | 159,33 | −74 726 | 20 119 555 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −50 | 126 745 | −0,04 | 157,82 | −7 891 | 20 002 896 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 640 | 126 795 | −1,28 | 156,87 | −257 267 | 19 890 332 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 480 | 128 435 | −4,09 | 155,74 | −853 455 | 20 002 467 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −4 452 | 133 915 | −3,22 | 155,25 | −691 173 | 20 790 304 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 122 | 138 367 | −1,51 | 155,69 | −330 383 | 21 542 939 |
2020-09-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 065 | 140 489 | −1,45 | 155,69 | −321 509 | 21 873 322 |
2020-08-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −9 262 | 142 554 | −6,10 | 158,17 | −1 464 959 | 22 547 595 |
2020-08-17 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 20 774 | 20 774 | |||||
2020-08-17 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 636 | 636 | |||||
2020-08-17 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 8 635 | 151 816 | 6,03 | ||||
2020-08-05 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 905 | 143 181 | −1,31 | 166,74 | −317 640 | 23 874 000 |
2020-08-05 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −10 375 | 145 086 | −6,67 | 166,10 | −1 723 288 | 24 098 785 |
2020-08-05 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −7 720 | 155 461 | −4,73 | 164,96 | −1 273 491 | 25 644 847 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 010 | 163 181 | −0,62 | 171,39 | −173 104 | 27 967 592 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −139 | 164 191 | −0,08 | 170,18 | −23 655 | 27 942 024 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 012 | 164 330 | −2,96 | 167,66 | −840 312 | 27 551 568 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −4 112 | 169 342 | −2,37 | 166,99 | −686 663 | 28 278 421 |
2020-07-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 300 | 173 454 | −0,74 | 165,86 | −215 618 | 28 769 080 |
2020-05-07 |
|
4 | NLTX |
Neoleukin Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −26 867 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −1 103 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −2 268 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −2 436 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −2 554 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −3 831 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 3 831 | 173 888 | 2,25 | 26,10 | 99 989 | 4 538 477 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 436 | 170 057 | 1,45 | 41,04 | 99 973 | 6 979 139 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 268 | 167 621 | 1,37 | 44,09 | 99 996 | 7 390 410 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 554 | 165 353 | 1,57 | 39,15 | 99 989 | 6 473 570 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 1 103 | 162 799 | 0,68 | 45,30 | 49 966 | 7 374 795 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −1 200 | 161 696 | −0,74 | 164,10 | −196 920 | 26 534 314 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −12 167 | 162 896 | −6,95 | 163,36 | −1 987 601 | 26 610 691 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −13 500 | 175 063 | −7,16 | 162,45 | −2 193 075 | 28 438 984 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 26 867 | 188 563 | 16,62 | 15,46 | 415 364 | 2 915 184 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −14 167 | 0 | −100,00 | ||||
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −14 167 | 161 696 | −8,06 | 147,00 | −2 082 556 | 23 769 393 | |
2020-05-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 14 167 | 175 863 | 8,76 | 12,00 | 170 004 | 2 110 356 | |
2020-04-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
D - Sale to Issuer | X | −570 | 161 696 | −0,35 | 139,92 | −79 752 | 22 623 906 |
2020-04-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 1 439 | 162 266 | 0,89 | ||||
2020-04-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 2 389 | 160 827 | 1,51 | ||||
2019-12-23 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 871 | 158 438 | 0,55 | ||||
2019-10-15 |
|
4 | NLTX |
Neoleukin Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 22 000 | 22 000 | |||||
2019-10-02 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −15 000 | 157 567 | −8,69 | 85,00 | −1 275 000 | 13 393 195 |
2019-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 092 | 172 567 | −1,20 | 70,80 | −148 112 | 12 217 623 |
2019-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 49 232 | 49 232 | |||||
2019-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 1 333 | 1 333 | |||||
2019-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 21 288 | 174 659 | 13,88 | ||||
2019-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 909 | 153 371 | −3,71 | 73,21 | −432 624 | 11 228 966 |
2019-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −12 500 | 159 280 | −7,28 | 80,00 | −1 000 000 | 12 742 400 |
2019-04-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −10 437 | 171 780 | −5,73 | 78,00 | −814 086 | 13 398 840 |
2019-04-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 063 | 182 217 | −1,12 | 78,00 | −160 914 | 14 212 926 |
2019-03-06 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −10 000 | 184 280 | −5,15 | 75,00 | −750 000 | 13 821 000 |
2018-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 47 904 | 47 904 | |||||
2018-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 1 301 | 1 301 | |||||
2018-09-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 20 715 | 194 280 | 11,94 | ||||
2018-08-29 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 427 | 173 565 | −3,03 | 74,23 | −402 856 | 12 884 042 |
2018-05-09 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 15 000 | 15 000 | |||||
2018-03-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-qualified Stock Option (Right to buy) |
A - Award | 10 526 | 10 526 | |||||
2017-11-03 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −534 | 178 992 | −0,30 | 61,59 | −32 889 | 11 024 117 |
2017-11-03 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −38 851 | 179 526 | −17,79 | 60,90 | −2 366 026 | 10 933 133 |
2017-09-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −9 638 | 218 377 | −4,23 | 52,00 | −501 176 | 11 355 604 | |
2017-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −4 937 | 228 015 | −2,12 | 47,89 | −236 455 | 10 920 664 |
2017-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 55 344 | 55 344 | |||||
2017-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 156 | 2 156 | |||||
2017-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 23 000 | 232 952 | 10,95 | ||||
2017-05-10 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 9 000 | 9 000 | |||||
2016-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 42 793 | 42 793 | |||||
2016-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 207 | 2 207 | |||||
2016-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 18 000 | 209 445 | 9,40 | ||||
2016-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −3 991 | 191 445 | −2,04 | 46,59 | −185 943 | 8 919 557 |
2016-05-11 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 7 500 | 7 500 | |||||
2015-10-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −6 468 | 0 | −100,00 | ||||
2015-10-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −8 333 | 0 | −100,00 | ||||
2015-10-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 8 333 | 194 675 | 4,47 | 12,00 | 99 996 | 2 336 100 | |
2015-10-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 6 468 | 186 342 | 3,60 | 15,46 | 99 995 | 2 880 847 | |
2015-08-25 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 39 946 | 39 946 | |||||
2015-08-25 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 554 | 2 554 | |||||
2015-08-25 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 17 000 | 179 874 | 10,44 | ||||
2015-08-25 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −5 825 | 162 874 | −3,45 | 42,02 | −244 794 | 6 844 731 |
2015-03-16 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 5 000 | 5 000 | |||||
2014-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 40 232 | 40 232 | |||||
2014-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 268 | 2 268 | |||||
2014-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 17 000 | 168 699 | 11,21 | ||||
2014-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −3 696 | 151 699 | −2,38 | 43,55 | −160 957 | 6 606 340 | |
2014-03-10 |
|
4 | AQXP |
AQUINOX PHARMACEUTICALS, INC
Stock Option (Right to Buy) |
A - Award | 8 333 | 8 333 | |||||
2014-03-06 | 3 | AQXP |
AQUINOX PHARMACEUTICALS, INC
No securities are beneficially owned |
0 | ||||||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −8 223 | 0 | −100,00 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −9 017 | 0 | −100,00 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −13 126 | 0 | −100,00 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 8 223 | 155 395 | 5,59 | 12,16 | 99 992 | 1 889 603 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 9 017 | 147 172 | 6,53 | 11,09 | 99 999 | 1 632 137 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 13 126 | 138 155 | 10,50 | 10,29 | 135 067 | 1 421 615 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −12 500 | 21 169 | −37,13 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −12 500 | 21 169 | −37,13 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −4 166 | 26 867 | −13,42 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −2 972 | 0 | −100,00 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −5 625 | 14 167 | −28,42 | ||||
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −12 500 | 125 029 | −9,09 | 41,45 | −518 095 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −12 500 | 125 029 | −9,09 | 41,45 | −518 095 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 12 500 | 137 529 | 10,00 | 26,10 | 326 250 | 3 589 507 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 12 500 | 137 529 | 10,00 | 26,10 | 326 250 | 3 589 507 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −4 166 | 125 029 | −3,22 | 41,45 | −172 671 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 4 166 | 129 195 | 3,33 | 15,46 | 64 406 | 1 997 355 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −5 625 | 125 029 | −4,31 | 41,45 | −233 143 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 5 625 | 130 654 | 4,50 | 12,00 | 67 500 | 1 567 848 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −2 972 | 125 029 | −2,32 | 41,45 | −123 182 | 5 182 152 | |
2013-08-30 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 972 | 128 001 | 2,38 | 12,16 | 36 140 | 1 556 492 | |
2013-08-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 33 564 | 33 564 | 41,04 | 1 377 467 | 1 377 467 | ||
2013-08-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 2 436 | 2 436 | 41,04 | 99 973 | 99 973 | ||
2013-08-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 14 400 | 125 029 | 13,02 | ||||
2013-08-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −3 328 | 110 629 | −2,92 | 40,91 | −136 148 | 4 525 832 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −29 166 | 31 033 | −48,45 | ||||
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −18 361 | 19 792 | −48,12 | ||||
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −29 166 | 113 957 | −20,38 | 37,94 | −1 106 558 | 4 323 529 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 29 166 | 143 123 | 25,59 | 15,46 | 450 906 | 2 212 682 | |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −18 361 | 113 957 | −13,88 | 37,94 | −696 616 | 4 323 529 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 18 361 | 132 318 | 16,11 | 12,00 | 220 332 | 1 587 816 | |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 486 | 2 972 | −33,33 | ||||
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −43 514 | 38 153 | −53,28 | ||||
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −43 514 | 113 957 | −27,63 | 36,94 | −1 607 407 | 4 209 572 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 43 514 | 157 471 | 38,18 | 12,00 | 522 168 | 1 889 652 | |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −1 486 | 113 957 | −1,29 | 36,94 | −54 893 | 4 209 572 |
2013-07-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 1 486 | 115 443 | 1,30 | 12,16 | 18 070 | 1 403 787 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −19 494 | 4 458 | −81,39 | ||||
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −682 | 0 | −100,00 | ||||
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −19 494 | 113 957 | −14,61 | 30,70 | −598 466 | 3 498 480 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 19 494 | 133 451 | 17,11 | 12,16 | 237 047 | 1 622 764 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −682 | 113 957 | −0,59 | 30,70 | −20 937 | 3 498 480 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 682 | 114 639 | 0,60 | 11,09 | 7 563 | 1 271 347 | |
2013-03-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −29 542 | 113 957 | −20,59 | 30,78 | −909 303 | 3 507 596 | |
2012-11-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −417 | 0 | −100,00 | ||||
2012-11-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
M - Exercise | −72 320 | 0 | −100,00 | ||||
2012-11-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 417 | 143 499 | 0,29 | 5,63 | 2 348 | 807 899 | |
2012-11-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 72 320 | 143 082 | 102,20 | 5,20 | 376 064 | 744 026 | |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −50 000 | 23 952 | −67,61 | ||||
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −50 000 | 70 762 | −41,40 | 28,97 | −1 448 500 | 2 049 975 |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 50 000 | 120 762 | 70,66 | 12,16 | 608 000 | 1 468 466 | |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −2 825 | 73 952 | −3,68 | ||||
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −42 175 | 682 | −98,41 | ||||
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −2 825 | 70 762 | −3,84 | 27,97 | −79 015 | 1 979 213 |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 2 825 | 73 587 | 3,99 | 12,16 | 34 352 | 894 818 | |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −42 175 | 70 762 | −37,34 | 27,97 | −1 179 635 | 1 979 213 |
2012-09-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 42 175 | 112 937 | 59,60 | 11,09 | 467 721 | 1 252 471 | |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −13 126 | 42 857 | −23,45 | ||||
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −17 874 | 0 | −100,00 | ||||
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −13 126 | 70 762 | −15,65 | 26,97 | −354 008 | 1 908 451 |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 13 126 | 83 888 | 18,55 | 11,09 | 145 567 | 930 318 | |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −17 874 | 70 762 | −20,17 | 26,97 | −482 062 | 1 908 451 |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 17 874 | 88 636 | 25,26 | 10,29 | 183 923 | 912 064 | |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −14 000 | 17 874 | −43,92 | ||||
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −14 000 | 70 762 | −16,52 | 26,97 | −377 580 | 1 908 451 |
2012-08-27 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 14 000 | 84 762 | 19,78 | 10,29 | 144 060 | 872 201 | |
2012-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 46 169 | 46 169 | 26,10 | 1 205 011 | 1 205 011 | ||
2012-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 3 831 | 3 831 | 26,10 | 99 989 | 99 989 | ||
2012-08-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 20 000 | 70 762 | 39,40 | ||||
2012-08-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −40 000 | 31 874 | −55,65 | ||||
2012-08-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −40 000 | 50 762 | −44,07 | 25,97 | −1 038 800 | 1 318 289 |
2012-08-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 40 000 | 90 762 | 78,80 | 10,29 | 411 600 | 933 941 | |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −19 583 | 0 | −100,00 | ||||
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −30 417 | 0 | −100,00 | ||||
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −19 583 | 50 762 | −27,84 | 24,97 | −488 988 | 1 267 527 |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 19 583 | 70 345 | 38,58 | 5,63 | 110 252 | 396 042 | |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −30 417 | 50 762 | −37,47 | 24,97 | −759 512 | 1 267 527 |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 30 417 | 81 179 | 59,92 | 5,20 | 158 168 | 422 131 | |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −45 000 | 30 417 | −59,67 | ||||
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −45 000 | 50 762 | −46,99 | 23,97 | −1 078 785 | 1 216 917 |
2012-06-14 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 45 000 | 95 762 | 88,65 | 5,20 | 234 000 | 497 962 | |
2012-06-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −35 000 | 75 417 | −31,70 | ||||
2012-06-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | X | −35 000 | 50 762 | −40,81 | 22,97 | −803 950 | 1 166 003 |
2012-06-08 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 35 000 | 85 762 | 68,95 | 5,20 | 182 000 | 445 962 | |
2006-02-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 19 583 | 19 583 | 5,63 | 110 252 | 110 252 | ||
2006-02-01 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Incentive Stock Option (right to buy) |
A - Award | 417 | 417 | 5,63 | 2 348 | 2 348 |